Home / Healthcare / Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016

Published: Jul 2016 | No Of Pages: 384 | Published By: GlobalData

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016" provides an overview of Refractory Acute Myeloid Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Acute Myeloid Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Refractory Acute Myeloid Leukemia 31
Jul 20, 2016: Actinium Pharmaceuticals Highlights Successful Investigator Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial 31
Jul 06, 2016: Actinium Pharmaceuticals to Sponsor Investigator Meeting for Pivotal Phase 3 SIERRA Trial for Iomab-B 32
Jun 29, 2016: Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA Trial 33
Jun 13, 2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1 34
Jun 09, 2016: Actinium Announces Strong Presence at Society of Nuclear Medicine and Molecular Imaging Annual Meeting 34
Jun 06, 2016: GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia 35
Jun 06, 2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress 36
Jun 06, 2016: Tolero Pharmaceuticals To Present Update On TP-1287 Program At 2016 EHA Congress 36
May 31, 2016: Syros Pharmaceuticals Announces FDA Acceptance of IND to Advance SY-1425 Into Phase 2 Clinical Trial 36
May 19, 2016: Astellas Oncology Announces Data on gilteritinib to be Presented at 2016 ASCO Annual Meeting 37
May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 37
Clinical Trial Profile Snapshots 38
Appendix 381
Abbreviations 381
Definitions 381
Research Methodology 382
Secondary Research 382
About GlobalData 383
Contact Us 383
Disclaimer 383
Source 384

Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2016* 6
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 382

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +